6:53 PM
 | 
Aug 28, 2008
 |  BC Extra  |  Clinical News

Takeda, Affymax suspend Hematide in CIA

Takeda (Tokyo:4502) and Affymax (NASDAQ:AFFY) will suspend development of Hematide to treat chemotherapy-induced anemia (CIA) and focus on developing the compound to treat anemia in chronic...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >